Abstract:KEYWORDS: Within the last year, the European Medicines Agency (EMA), Food and Drug Administration (FDA) and the Medicines and Healthcare Products Regulatory Agency in the United Kingdom (MHRA) began investigations into whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are causally related to suicidality [ Citation 1 , Citation 2 ]. The impetus for investigation was provided by reports of self-injury and suicidal thoughts associated with exposure to GLP-1 RAs.

What problem does this paper attempt to address?

The paper attempts to address the question of whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with suicidal tendencies. Specifically, the paper explores the following aspects: 1. **Regulatory Investigations**: The European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have begun investigating the causal relationship between GLP-1 RAs and suicidal tendencies over the past year. These investigations were prompted by reports of self-harm and suicidal thoughts following the use of GLP-1 RAs. 2. **Review of Existing Evidence**: The paper reviews data from pharmacoepidemiology and pharmacovigilance studies to analyze the relationship between GLP-1 RAs and suicidal tendencies. The authors note that although some reports suggest a possible link between GLP-1 RAs and suicidal tendencies, the existing data are insufficient to establish a causal relationship. 3. **Potential Therapeutic Benefits**: The paper also discusses the potential therapeutic benefits of GLP-1 RAs in patients with mental disorders, particularly in treating antipsychotic-induced weight gain (PDWG). Studies indicate that GLP-1 RAs have potential in improving cognitive function and metabolic parameters, with no observed negative impact on psychiatric symptoms or suicidal tendencies. 4. **Future Research Directions**: The paper proposes future research directions, emphasizing the need for further clinical trials and pharmacoepidemiological studies to comprehensively assess the relationship between GLP-1 RAs and suicidal tendencies. Additionally, the authors suggest enhancing suicide risk screening and management in clinical practice for patients using GLP-1 RAs. Overall, the paper aims to systematically evaluate the relationship between GLP-1 RAs and suicidal tendencies and provide guidance for future clinical practice and research.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas